文献速递临床试验与 GCP基础与转化研究

益智安神颗粒对遗忘型轻度认知障碍老年人认知和睡眠质量的有效性:随机双盲安慰剂对照试验方案

Effectiveness of Yi-Zhi-An-Shen granules on cognition and sleep quality in older adults with amnestic mild cognitive impairment: protocol for a randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2019-08-20

本研究为随机双盲安慰剂对照试验方案,计划招募80例60-85岁遗忘型轻度认知障碍(aMCI)患者,按1:1随机分配至治疗组或安慰剂组,每日三次服用益智安神颗粒(YZASG)或等剂量安慰剂,干预16周并随访18个月。主要结局为阿尔茨海默病评估量表-认知分量表,次要结局包括简易精神状态检查、蒙特利尔认知评估、匹兹堡睡眠质量指数、血清免疫与炎症因子浓度及粪便微生物群。研究旨在评估YZASG对aMCI老年人整体认知的有效性与安全性,并通过睡眠质量、肠道微生物16S核糖体DNA与宏基因组分析及血清标志物探讨其潜在机制。

要点

  • 方案计划纳入80例60-85岁aMCI患者,按1:1随机分配至益智安神颗粒组或安慰剂组。
  • 干预为每日三次服用YZASG或等剂量安慰剂,疗程16周,随访18个月。
  • 主要结局为ADAS-Cog,次要结局包括MMSE、MoCA、PSQI、血清标志物及粪便微生物群。

核心结论

  • 试验结果将有助于评估YZASG干预老年人aMCI的认知安全性和有效性,并确定其是否通过改善睡眠质量、调节肠道微生物群及某些血清标志物浓度而发挥作用。

研究设计与样本

  • 本研究为随机、双盲、安慰剂对照临床试验方案。
  • 计划招募80例60-85岁aMCI患者,按1:1比例随机分配至治疗组和安慰剂组。
  • 干预疗程16周,随访18个月。

关键数值与推荐

  • 主要结局为阿尔茨海默病评估量表-认知分量表(ADAS-Cog)。
  • 次要结局包括简易精神状态检查(MMSE)、蒙特利尔认知评估(MoCA)、匹兹堡睡眠质量指数(PSQI)、血清免疫因子和炎症细胞因子浓度及粪便微生物群。
  • 粪便微生物群仅在干预基线和终点采集。
  • 治疗组每日三次服用YZASG,安慰剂组每日三次服用等剂量安慰剂。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Amnestic mild cognitive impairment (aMCI) is a syndrome characterized by significant forgetfulness that does not meet the criteria of dementia. Individuals with aMCI are at greater risk of progressing to dementia. Current studies suggest that good sleep quality is linked with preserved cognition in the elderly, and sleep complaints are common among the elderly with amnesia. Therefore, improving their sleep may be helpful for maintaining and improving their cognitive capacity. According to the theory of traditional Chinese medicine, Yi-Zhi-An-Shen is an herbal compound which may ameliorate forgetfulness and sleep disorders. As growing evidence indicates that the gut microbiome is associated with major mental symptoms, a hypothesis was proposed that Yi-Zhi-An-Shen granules (YZASG) might work by alternating microbial abundance and diversity. In this study, the investigators intend to assess the efficacy of YZASG on global cognition in the elderly suffering from aMCI and evaluate its safety as well as its potential mechanisms via sleep quality, fecal microbial 16S ribosomal DNA and metagenomics analyses, and serum markers. METHODS/DESIGN: This study is a randomized, double-blind, placebo-controlled clinical trial. A total of 80 patients (aged 60-85 years) will be recruited and allocated randomly to a treatment group and a placebo group in a 1:1 ratio and will then be administered YZASG or isodose placebo three times a day. The intervention course is 16 weeks, with an 18 months follow-up. The primary outcome is the Alzheimer's Disease Assessment Scale-Cognitive Subscale. Secondary outcome measures are the Mini-Mental State Examination, Montreal Cognitive Assessment, Pittsburgh Sleep Quality Index, serum concentrations of immunological factors and inflammatory cytokines, and fecal microbiota. Fecal microbiota will only be collected at the baseline and endpoint of the intervention. DISCUSSION: The results of this trial will be conducive to assessing the safety and effectiveness on cognition of YZASG in intervening aMCI among the elderly and determining if it takes effect via the improvement of sleep quality, regulation of gut microbiota, and concentration of certain serum markers. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03601000 . Registered on 26 July 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Yue S, He T, Li B, et al. Effectiveness of Yi-Zhi-An-Shen granules on cognition and sleep quality in older adults with amnestic mild cognitive impairment: protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2019. PMID: 31429790. doi:10.1186/s13063-019-3607-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。